The fifth seasonImran insists on demands to put off civil disobedience
In response to statements on recent verdicts by military courts, the Foreign Office (FO) on Tuesday said that the judgments were made under a law enacted by the parliament and in line with the ruling of the Supreme Court of Pakistan. In a statement, FO spokesperson Mumtaz Zahra Baloch said: “Pakistan is fully committed to fulfilling all its international human rights obligations.” She said that Pakistan’s legal system is consistent with international human rights law, including provisions of the International Covenant on Civil and Political Rights (ICCPR). “It has remedies of judicial review by the superior courts and guarantees promotion and protection of human rights and fundamental freedoms.” The spokesperson added that Islamabad believes in constructive and productive dialogue to promote principles of democracy, human rights and the rule of law. “We remain fully committed to implementing our commitments under the GSP Plus Scheme and core international human rights conventions.” The FO spokesperson said that they would continue to engage with their international partners including the European Union to uphold the international human rights law, without any discrimination and double standards. The military court last week sentenced 25 individuals involved in the attacks on state installations during the violent protests of May 9, 2023. The violent protests broke out after Pakistan Tehreek-e-Insaf (PTI) founder Imran Khan was taken into custody in a graft case. In turn, scores of party workers were arrested and more than 100 civilians are facing military trials. However, the Khan-founded party maintained that it had no role in the incidents involving military installations, including the attack on the General Headquarters (GHQ), and has called for a judicial probe into last year's events. Following the verdict, the European Union, United Kingdom and the United States expressed concerns over the recent sentencing of civilians by the military courts. Earlier today, the US expressed "deep concern" over the conviction of 25 civilians in a military tribunal in Pakistan, claiming the military courts lacked judicial independence, transparency, and due process guarantees. In a brief statement issued today, US Department of State Spokesperson Matthew Miller said that the Washington continued to call on Pakistani authorities to "respect" the right to a fair trial and due process, as enshrined in the country's constitution. The UK also urged the federal government to uphold its obligations under the ICCPR. "Military courts lack transparency, independent scrutiny and undermine the right to a fair trial," a Foreign, Commonwealth & Development Office spokesperson said in a statement issued on Monday. However, the spokesperson said, the UK respects Pakistan’s sovereignty over its own legal proceedings. The EU was the first to react on the matter, expressing concern over the sentencing of 25 accused by a military court, saying that the verdicts were seen as inconsistent with the obligations that Pakistan has undertaken under the ICCPR. "In line with article 14 of ICCPR, every person is entitled to a fair and public trial in a court that is independent, impartial and competent, and has the right to adequate and effective legal representation," said a statement issued by the EU's European External Action Service. Furthermore, it said, article 14 also stipulates that any "judgement rendered in a criminal case shall be made public". Under the EU's Generalised Scheme of Preferences Plus (GSP+), beneficiary countries, including Pakistan, have voluntarily agreed to implement effectively 27 international core conventions — including the ICCPR — in order to continue benefitting from GSP+ status, the statement added.AP Sports SummaryBrief at 6:05 p.m. ESTShare Tweet Share Share Email The Hippoo Woocommerce app simplifies the complexities of managing a WooCommerce store, ensuring accessibility and efficiency for users of all technical backgrounds. Whether you run a small shop or a large online business, Hippoo! makes store management effortless and effective. It’s available for both iOS and Android platforms. This makes it easy to stay in sync no matter which devices you use. Key features: Efficient Order Fulfillment: With Hippoo!, you’ll be sailing through your orders in no time. A tap here, a swipe there, and you’re all set to keep track of orders, ensuring your customers are always satisfied. Seamless Inventory Management: Keeping up with stock levels is a breeze with Hippoo! The app will alert you when items are running low, making sure you never sell what you don’t have. Barcode Scanning: Hippoo! offers a handy barcode or SKU scanning feature. You can quickly find products, change details, and manage variations, all while you’re on the move. Improved Customer Engagement: Hippoo! helps you stay close to your customers. See their recent reviews, respond to feedback quickly, and continue delivering outstanding service. Insightful Analytics: Hippoo! puts the power of data in your hands. Discover which products are in demand, track your sales trends, and use these insights to steer your shop in the right direction. Instant Notifications: Receive real-time notifications when orders are received or when products are low in stock, ensuring you never miss a beat in managing your WooCommerce store. Hands-On with Hippoo WooComerce admin app Order Management The Hippoo Woocommerce app simplifies order management. View all of your orders, including information like customer names, order IDs, payment and shipping methods, and item details. Each order can be expanded for more information. Access and manage order notes with a simple tap, and add private notes or notes for customers effortlessly. Changing order statuses is just as easy, and the app also includes a search bar for quick order lookup as well as a barcode scanning feature to find orders directly from their invoices. Product Management Managing your products is intuitive withthe Hippoo Woocommerce app. Just tap on the product icon in the main menu to view your inventory. At a glance, see each product’s image, name, price, SKU, and stock status. Editing a product is straightforward as well. The app also offers easy options to share products on social media. Out-of-Stock List A standout feature of Hippoo! is its powerful out-of-stock list, crucial for maintaining effective inventory control. This tool enables real-time monitoring of stock levels, helping you stay on top of your inventory. When products go out of stock, simply tap the ‘Out of Stock’ button in the main menu to view and manage these items effortlessly. Restocking is a breeze, ensuring your store is always stocked with popular products. Intuitive Orders Page The orders page in Hippoo is designed for convenience, providing a summary of orders and the ability to expand the page and print order invoices or shipping labels directly within the app. Built-in Barcode Scanner Hippoo includes a barcode scanner to quickly find orders by scanning order IDs or product SKU barcodes. Additionally, the Hippoo WooCommerce plugin generates barcodes for seamless order management from desktop to mobile. Multishop Feature With Hippoo, you can manage multiple shops within a single app and easily switch between them, streamlining the management process for multiple stores. Expandable Extensions Features Hippoo Woocommerce app is highly customizable with a range of extensions like Hippoo Notifications, Hippoo Popups, and Hippoo Tickets, allowing you to add functionalities as needed. Conclusion The Hippoo! app is not just another app for WooCommerce; it’s the ultimate solution for efficient online store management—saving you valuable time and effort. Plus, with everything managed in one place, running your online store becomes a much more enjoyable experience. Users consistently report transformative improvements in their WooCommerce store operations with the Hippoo! App. Why not experience the same benefits yourself? Install the Hippoo plugin on your WordPress website and download the app from the Apple App Store or Google Play Store today . Related Items: Hippoo App , WooCommerce Share Tweet Share Share Email Recommended for you MaxelPay Launches Cryptocurrency Payment Gateway Plugin for WooCommerce An Introduction to WooCommerce: The Ultimate Guide to WordPress E-Commerce WooCommerce POS Security: Best Practices for Safeguarding Transactions CommentsWASHINGTON — Only about 2 in 10 Americans approve of President Joe Biden's decision to pardon his son Hunter after earlier promising he would do no such thing, according to a poll from The Associated Press-NORC Center for Public Affairs Research. That displeasure tracks with the bipartisan uproar in Washington that ignited over the president's about-face. The survey found that a relatively small share of Americans "strongly" or "somewhat" approve of the pardon, which came after the younger Biden was convicted on gun and tax charges. About half said they "strongly" or "somewhat" disapprove, and about 2 in 10 neither approve nor disapprove. The Democratic president said repeatedly that he would not use his pardon power for the benefit of his family, and the White House continued to insist, even after Republican Donald Trump's election win in November, that Biden's position had not changed — until it suddenly did. Hunter Biden leaves federal court Sept. 5 in Los Angeles after pleading guilty to federal tax charges. "I know it's not right to believe politicians as far as what they say compared to what they do, but he did explicitly say, 'I will not pardon my son,'" said Peter Prestia, a 59-year-old Republican from Woodland Park, New Jersey, just west of New York City, who said he strongly disagreed with the move. "So, it's just the fact that he went back on his word." In issuing a pardon Dec. 1, Biden argued that the Justice Department had presided over a "miscarriage of justice" in prosecuting his son. The president used some of the same kind of language that Trump does to describe the criminal cases against him and his other legal predicaments. White House press secretary Karine Jean-Pierre said it was a decision that Biden struggled with but came to shortly before he made the announcement, "because of how politically infected these cases were" as well as "what his political opponents were trying to do." The poll found that about 4 in 10 Democrats approve of the pardon, while about 3 in 10 disapprove and about one-quarter did not have an opinion or did not know enough to say. The vast majority of Republicans and about half of independents had a negative opinion. President Joe Biden and son Hunter Biden walk Nov. 29 in downtown Nantucket Mass. For some, it was easy to see family taking priority over politics. "Do you have kids?" asked Robert Jenkins, a 63-year-old Democrat who runs a lumber yard and gas station in Gallipolis, Ohio. "You're gonna leave office and not pardon your kid? I mean, it's a no-brainer to me." But Prestia, who is semiretired from working for a digital marketing conglomerate, said Biden would have been better off not making promises. "He does have that right to pardon anybody he wants. But he just should have kept his mouth shut, and he did it because it was before the election, so it's just a bold-faced lie," Prestia said. Despite the unpopularity of his decision, the president's approval rating has not shifted meaningfully since before his party lost the White House to Trump. About 4 in 10 Americans "somewhat" or "strongly" approve of the way Biden is handling his job as president, which is about where his approval rating stood in AP-NORC polls since January 2022. Still, the pardon keeps creating political shock waves, with Republicans, and even some top Democrats, decrying it. Older adults are more likely than younger ones to approve of Biden's pardoning his son, according to the poll, though their support is not especially strong. About one-third of those ages 60 and older approve, compared with about 2 in 10 adults under 60. The age divide is driven partially by the fact that younger adults are more likely than older ones to say they neither approve nor disapprove of the pardon or that they do not know enough to say. President Joe Biden walks with his son Hunter Biden on July 26 as he heads toward Marine One on the South Lawn of the White House in Washington. About 6 in 10 white adults disapprove of the pardon, compared with slightly less than half of Hispanic adults and about 3 in 10 Black adults. Relatively large shares of Black and Hispanic Americans — about 3 in 10 — were neutral, the poll found. "Don't say you're gonna do something and then fall back," said Trinell Champ, 43, a Democrat from Nederland, Texas, who works in the home health industry and said she disapproved of the pardon. "At the end of the day, all you have is your word." Champ, who is Black, voted for Democratic Vice President Kamala Harris over Trump. "I just had my hopes up for her, but I wasn't 100% positive," she said. Champ also said she does not approve of Biden's handling of the presidency and thinks the country is on the wrong track. "While he was in office, I felt like I really didn't see a lot of changes," she said. "I just felt like everything just kind of stayed the same," Champ said. Overall, though, the pardon did not appear to be a driving factor in many Americans' assessment of Biden's job performance. The share of Black Americans who approve of the way he is handling his job as president did fall slightly since October, but it is hard to assess what role the pardon may have played. Sen. Joe Biden (D-Del.) carries both of his sons, Joseph R. III, left, and Robert H., during an appearance at the Democratic state convention last summer, 1972. At center is his wife Neilia Biden, who was killed in an auto crash, Dec. 20, 1972. With them are Governor-elect Sherman W. Tribbitt and his wife, Jeanne. (AP Photo) Joseph Biden, the newly-elected Democratic Senator from Delaware, is shown in Washington, Dec. 12, 1972. (AP Photo/Henry Griffin) 1972 - Is first elected to the Senate at age 29, defeating Republican Senator J. Caleb Boggs. Wins re-election in 1978, 1984, 1990, 1996 and 2002. The newly-elected Democratic senator from Delaware, Joe Biden, is shown, Dec. 13, 1972. Sen. Joe Biden (D-Del.) kisses the cheek of an unidentified friend who offered consoling words after a memorial service in Wilmington, Del., Dec. 22, 1972, for Biden's wife Neilia, their 13-month-old daughter Naomi Christina, who perished in a car-truck crash. Biden's two sons were hospitalized with serious injuries. (AP Photo/Bill Ingraham) December 18, 1972 - While Christmas shopping, Biden's first wife, Neilia Hunter Biden, and daughter, Naomi Biden, are killed in a car accident. His sons are badly injured, but survive. January 5, 1973 - Is sworn in as US senator of Delaware at son Beau Biden's bedside in the hospital. In this Jan. 5, 1973 file photo, four-year-old Beau Biden, foreground, plays near his father, Joe Biden, center, being sworn in as the U.S. senator from Delaware, by Senate Secretary Frank Valeo, left, in ceremonies in a Wilmington hospital. Beau was injured in an accident that killed his mother and sister in December 1972. Biden's father, Robert Hunter, holds the Bible. (AP Photo/File) 1987-1995 - Chairman of the Senate Committee on the Judiciary. Sen. Joe Biden (D-Del.), chairman of the Senate Judiciary Committee, rubs his temples while speaking during confirmation hearings for Supreme Court nominee Robert H. Bork, Sept. 17, 1987, on Capitol Hill. (AP Photo/John Duricka) June 9, 1987 - Enters the 1988 presidential race, but drops out three months later following reports of plagiarism and false claims about his academic record. Sen. Joe Biden (D-Del.) waves from his train as he leaves Wilmington, Del., after announcing his candidacy for president, June 9, 1987. At right, son Beau carries daughter; to Biden's right is his wife Jill and son Hunter. (AP Photo/George Widman) February 1988 - Undergoes surgery to repair an aneurysm in an artery that supplies blood to the brain. Sen. Joseph Biden (D-Del.), wearing a University of Delaware baseball cap, leaves Walter Reed Army Hospital accompanied by his son Hunter Biden, Thursday, March 24, 1988, Washington, D.C. Biden had been in the hospital for 11 days so that surgeons could implant a small umbrella-like filter in a vein to prevent blood clots from reaching his lungs. (AP Photo/Adele Starr) In this Oct. 12, 1991 file photo Senate Judiciary Committee Chairman Joe Biden, D-Del., points angrily at Clarence Thomas during comments at the end of hearings on Thomas' nomination to the Supreme Court on Capitol Hill. Sen. Edward Kennedy, D-Mass. looks on at right. (AP Photo/Greg Gibson, File) January 20, 1990 - Introduces a bill that becomes the Violence Against Women Act (VAWA). The act addresses sexual assault and domestic violence. It is signed into law by President Bill Clinton in 1994. Sen. Joe Biden (D-Del.), left, stands behind a flag as Sen. Barbara Boxer (D-Calif.), second from right, along with other congresswomen meet reporters on Capitol Hill, Feb. 24, 1993, to discuss the Violence Against Women Act. From left are: Sen. Biden; Rep. Louise Slaughter (D-N.Y.); Rep. Pat Schroeder (D-Colo); Sen. Boxer; and Rep. Constance Morella of Maryland. (AP Photo/Barry Thumma) In this April 9, 1993, file photo Sen. Joe Biden, D-Del. stands in front of a Danish armored personnel carrier at the UN-controlled Sarajevo Airport, making a statement about his trip to the besieged Bosnian capital. (AP Photo/Michael Stravato, File) Sen. Joseph Biden, D-Del., ranking Democrat on the Senate Foreign Relations Committee, meets reporters on Capitol Hill Thursday, Oct. 16, 2003 to discuss the United Nations-Iraq vote. (AP Photo/Terry Ashe) Democratic presidential hopeful, and Senate Foreign Relations Committee Chairman Sen. Joseph Biden, D-Del., presides over a hearing of the committee on Capitol Hill in Washington, Thursday, Feb. 1, 2007 to discuss the remaining options in Iraq. (AP Photo/Dennis Cook) Democratic presidential hopeful U.S. Sen. Joseph Biden D-Del., smiles during the Iowa Federation of Labor, AFL-CIO Presidential Forum Wednesday, Aug. 15, 2007, in Waterloo, Iowa. (AP Photo/M. Spencer Green) January 31, 2007 - Files a statement of candidacy with the Federal Elections Commission to run for president. August 1, 2007 - His memoir, "Promises to Keep: On Life and Politics," is published. Sen. Joe Biden, D-Del., left, listens as Sen. Barack Obama, D-Ill., responds to a question during the first Democratic presidential primary debate of the 2008 election hosted by the South Carolina State University in Orangeburg, SC., Thursday, April 26, 2007. At right is Sen. Hillary Rodham Clinton, D-NY. (AP Photo/J. Scott Applewhite) Sen. Joseph Biden, D-Del., speaks at a Caucus night rally in Des Moines, Iowa, Thursday, Jan. 3, 2008. Biden abandoned his bid for the Democratic presidential nomination Thursday after a poor showing in the state's caucuses. (AP Photo/Jeff Chiu) In this Jan. 3, 2008, file photo, Democratic presidential hopeful, Sen. Joe Biden, D-Del., rests his head on the shoulder of his wife, Jill, as they stand in a hallway awaiting his introductions for a rally at the UAW Hall in Dubuque, Iowa on the day of the Iowa caucus in Dubuque, Iowa. (AP Photo/Mark Hirsch, File) August 23, 2008 - Is named the vice-presidential running mate of Barack Obama. In this Aug. 23, 2008 file photo, Democratic presidential candidate Sen. Barack Obama D-Ill., and his vice presidential running mate Sen. Joe Biden, D-Del., appear together in Springfield, Ill. (AP Photo/M. Spencer Green, file) In this Sept. 16, 2008 file photo, then Democratic vice presidential candidate Sen. Joe Biden, D-Del. arrives by Amtrak in Wilmington, Del., (AP Photo/Gerald Herbert, File) In this Oct. 2,2008 file photo, Democratic vice presidential candidate Sen. Joe Biden, D-Del., left, and Republican vice presidential candidate Alaska Gov. Sarah Palin face off during the vice presidential debate at Washington University in St. Louis. (AP Photo/Tom Gannam, File) November 4, 2008 - Is elected vice president of the United States. President-elect Barack Obama, left, and Vice President-elect Joe Biden wave to the crowd after Obama's acceptance speech at his election night party at Grant Park in Chicago before giving his acceptance speech Tuesday night, Nov. 4, 2008. (AP Photo/Morry Gash) January 20, 2009 - Is sworn in as vice president of the United States. Vice President Joe Biden, left, with his wife Jill at his side, taking the oath of office from Justice John Paul Stevens at the U.S. Capitol in Washington, Tuesday, Jan. 20, 2009. (AP Photo/Elise Amendola) February 7, 2009 - Delivers his first major speech as vice president at a security conference in Germany. US Vice President Joe Biden addresses the participants of the International Conference on Security Policy, Sicherheitskonferenz, at the hotel "Bayerischer Hof" in Munich, southern Germany, on Saturday, Feb. 7, 2009. September 1, 2010 - Presides over a ceremony in Iraq to formally mark the end of the US combat mission in Iraq. US Vice President Joe Biden, left, US Secretary of Defense Robert Gates, center, and Chairman of the Joint Chiefs Admiral Mike Mullen, right, stand while the US National Anthem is played during the United States Forces-Iraq change of command ceremony in Baghdad on Wednesday Sept. 1, 2010, as a new US military mission in Iraq was launched ending seven years of combat. (AP Photo/Jim Watson Pool) November 6, 2012 - Obama and Biden are reelected, defeating Mitt Romney and Paul Ryan. Vice President Joe Biden exits with his wife Jill Biden after voting at Alexis I. duPont High School, Tuesday, Nov. 6, 2012, in Greenville, Del. (AP Photo/Matt Rourke) Vice President Joe Biden, with his wife Jill Biden, center, holding the Biden Family Bible, shakes hands with Supreme Court Justice Sonia Sotomayor after taking the oath of office during an official ceremony at the Naval Observatory, Sunday, Jan. 20, 2013, in Washington. (AP Photo/Carolyn Kaster) October 2, 2014 - Speaking at the John F. Kennedy School of Government at Harvard University, Biden tells attendees that ISIS has been inadvertently strengthened by actions taken by Turkey, the UAE and other Middle Eastern allies to help opposition groups fighting against Syrian President Bashar al-Assad. In this Thursday, Oct. 2, 2014 file photo, Vice President Joe Biden speaks to students, faculty and staff at Harvard University in Cambridge, Mass. Biden is due to headline a Democratic campaign rally in Las Vegas, with a downtown appearance Monday, Oct. 6, 2014, to talk about raising the minimum wage. (AP Photo/Winslow Townson,File) May 30, 2015 - Biden's eldest son, Beau Biden, passes away from brain cancer at age 46. In this June 6, 2015 file photo, Vice President Joe Biden, accompanied by his family, holds his hand over his heart as he watches an honor guard carry a casket containing the remains of his son, former Delaware Attorney General Beau Biden, into St. Anthony of Padua Roman Catholic Church in Wilmington, Del. for funeral services. Beau Biden died of brain cancer May 30 at age 46. (AP Photo/Patrick Semansky) October 21, 2015 - Says he will not seek the presidency, announcing that the window for a successful campaign "has closed." December 6, 2016 - Doesn't rule out running for president in 2020, saying "I'm not committing not to run. I'm not committing to anything. I learned a long time ago fate has a strange way of intervening." President Barack Obama hugs Vice President Joe Biden as Biden waves at the end Biden's announcement in the Rose Garden of the White House in Washington, Wednesday, Oct. 21, 2015, that he will not run for the presidential nomination. Jill Biden is at right. (AP Photo/Jacquelyn Martin) Vice President Joe Biden pauses between mock swearing in ceremonies in the Old Senate Chamber on Capitol Hill in Washington, Tuesday, Jan. 3, 2017, as the 115th Congress begins. (AP Photo/Alex Brandon) January 12, 2017 - Obama surprises Biden by presenting him the Presidential Medal of Freedom, the nation's highest civilian honor, during a White House ceremony. President Barack Obama presents Vice President Joe Biden with the Presidential Medal of Freedom during a ceremony in the State Dining Room of the White House in Washington, Thursday, Jan. 12, 2017. (AP Photo/Susan Walsh) February 1, 2017 - Biden and his wife, Jill Biden, launch the Biden Foundation, an organization that will work on seven issues: foreign policy; Biden's cancer initiative; community colleges and military families; protecting children; equality; ending violence against women; and strengthening the middle class. February 7, 2017 - Is named the Benjamin Franklin presidential practice professor at the University of Pennsylvania, where he will lead the Penn Biden Center for Diplomacy and Global Engagement. He will also serve as the founding chair of the University of Delaware's Biden Institute, the university announces. March 1, 2017 - Biden receives the Congressional Patriot Award from the Bipartisan Policy Center. He receives the honor in recognition of his work crafting bipartisan legislation with Republicans and Democrats. Former Vice President Joe Biden tucks notes into his jacket after speaking at an event to formally launch the Biden Institute, a research and policy center focused on domestic issues at the University of Delaware, in Newark, Del., Monday, March 13, 2017. (AP Photo/Patrick Semansky) In this March 26, 2019, file photo, former Vice President Joe Biden speaks at the Biden Courage Awards in New York. (AP Photo/Frank Franklin II, File) April 25, 2019 - Announces he is running for president in a campaign video posted to social media. Hours later, the Biden Foundation board chair, Ted Kaufman, announces the immediate suspension of all the organization's operations. Former Vice President and Democratic presidential candidate Joe Biden arrives at the Wilmington train station Thursday April 25, 2019 in Wilmington, Delaware. Biden announced his candidacy for president via video on Thursday morning. (AP Photo/Matt Slocum) In this June 6, 2019, file photo, Democratic presidential candidate former Vice President Joe Biden speaks during the "I Will Vote" fundraising gala in Atlanta. Biden shifted to oppose longstanding restrictions on federal funding of abortion during his remarks. (AP Photo/John Bazemore, File) Democratic presidential candidate, former Vice President Joe Biden signs a copy of his book "Promise Me, Dad" at a campaign rally at Modern Woodmen Park, Sunday, Jan. 5, 2020, in Davenport, Iowa. (AP Photo/Andrew Harnik) Democratic presidential candidate former Vice President Joe Biden speaks at a primary night election rally in Columbia, S.C., Saturday, Feb. 29, 2020 after winning the South Carolina primary. (AP Photo/Gerald Herbert) Democratic presidential candidate former Vice President Joe Biden speaks at a primary night election rally in Columbia, S.C., Saturday, Feb. 29, 2020, after winning the South Carolina primary. (AP Photo/Matt Rourke) Democratic presidential candidate former Vice President Joe Biden speaks at a primary election night campaign rally Tuesday, March 3, 2020, in Los Angeles. (AP Photo/Chris Carlson) August 20, 2020: Joe Biden accepts the Democratic nomination for president Democratic presidential candidate former Vice President Joe Biden speaks during the fourth day of the Democratic National Convention, Thursday, Aug. 20, 2020, at the Chase Center in Wilmington, Del. (AP Photo/Andrew Harnik) Democratic presidential candidate former Vice President Joe Biden, with Democratic vice presidential candidate Sen. Kamala Harris, D-Calif., raise their arms up as fireworks go off in the background during the fourth day of the Democratic National Convention, Thursday, Aug. 20, 2020, at the Chase Center in Wilmington, Del. Looking on are Jill Biden, far left, and Harris' husband Doug Emhoff, far right. (AP Photo/Andrew Harnik) President Donald Trump, left, and Democratic presidential candidate former Vice President Joe Biden, right, with moderator Chris Wallace, center, of Fox News during the first presidential debate Tuesday, Sept. 29, 2020, at Case Western University and Cleveland Clinic, in Cleveland, Ohio. (AP Photo/Patrick Semansky) Democratic presidential candidate former Vice President Joe Biden, right, and former President Barack Obama greet each other with an air elbow bump, at the conclusion of rally at Northwestern High School in Flint, Mich., Saturday, Oct. 31, 2020. (AP Photo/Andrew Harnik) Democratic presidential candidate former Vice President Joe Biden arrives to speak at a rally at Belle Isle Casino in Detroit, Mich., Saturday, Oct. 31, 2020, which former President Barack Obama also attended. (AP Photo/Andrew Harnik) President-elect Joe Biden gestures on stage after speaking, Saturday, Nov. 7, 2020, in Wilmington, Del. (AP Photo/Andrew Harnik, Pool) FILE - In this Saturday, Nov. 7, 2020, file photo, from left, Doug Emhoff, husband of Vice President-elect Kamala Harris, Harris, President-elect Joe Biden and his wife, Jill Biden, stand on stage together, in Wilmington, Del. The theme for Biden’s inauguration will be “America United." Unity is an issue that’s long been a central focus for Biden but one that’s taken on added weight in the wake of the violence at the U.S. Capitol. (AP Photo/Andrew Harnik, Pool, File) President-elect Joe Biden announces his climate and energy team nominees and appointees at The Queen Theater in Wilmington Del., Saturday, Dec. 19, 2020. (AP Photo/Carolyn Kaster) President Joe Biden speaks about his domestic agenda from the East Room of the White House in Washington on Oct. 28, 2021. (AP Photo/Susan Walsh) U.S. President Joe Biden, left, shakes hands with Pope Francis as they meet at the Vatican on Oct. 29, 2021. (Vatican Media via AP) President Joe Biden removes his face mask as he arrives in the East Room of the White House to speak about the evacuation of American citizens, their families, special immigrant visa applicants and vulnerable Afghans on Aug. 20, 2021, in Washington. (AP Photo/Manuel Balce Ceneta) Cherelle Griner, wife of WNBA star Brittney Griner, speaks after President Joe Biden announced Brittney Griner's release in a prisoner swap with Russia on Dec. 8, 2022, in the Roosevelt Room of the White House in Washington. Also attending are Secretary of State Antony Blinken, left, and Vice President Kamala Harris. President Joe Biden holds the microphone to Chocolate, the national Thanksgiving turkey, during a pardoning ceremony Nov. 21, 2022, at the White House in Washington. President Joe Biden holds an Atlanta Braves jersey during an event celebrating the Major League Baseball 2021 World Series champion Atlanta Braves in the East Room of the White House on Sept. 26, 2022, in Washington. President Joe Biden receives his COVID-19 booster from a member of the White House medical unit during an event in the South Court Auditorium on the White House campus on Oct. 25, 2022, in Washington. President Joe Biden and first lady Jill Biden arrive to give treats to trick-or-treaters on the South Lawn of the White House, on Halloween on Oct. 31, 2022, in Washington. U.S. President Joe Biden, left, talks with Indonesian President Joko Widodo during their bilateral meeting ahead of the G20 Summit in Nusa Dua, Bali, Indonesia, on Nov. 14, 2022. U.S. President Joe Biden, right, and Chinese President Xi Jinping shake hands before a meeting on the sidelines of the G20 summit meeting Nov. 14, 2022, in Bali, Indonesia. President Joe Biden is greeted by Israeli Prime Minister Benjamin Netanyahu after arriving at Ben Gurion International Airport on Oct. 18, 2023, in Tel Aviv. President Joe Biden speaks from the Oval Office of the White House on Oct. 19, 2023, in Washington, about the war in Israel and Ukraine. President Joe Biden arrives to speak at the Amtrak Bear Maintenance Facility on Nov. 6, 2023, in Bear, Del. President Joe Biden, accompanied by Office of Management and Budget director Shalanda Young, left, and Women's Alzheimer's Movement founder Maria Shriver, right, gives first lady Jill Biden a kiss after giving her the pen he used to sign a presidential memorandum that will establish the first-ever White House Initiative on Women's Health Research in the Oval Office of the White House on Nov. 13, 2023, in Washington. President Joe Biden pauses as he speaks to reporters in Nantucket, Mass. on Nov. 26, 2023, about hostages freed by Hamas in a third set of releases under a four-day cease-fire deal between Israel and Hamas. President Joe Biden shakes hands with Ukrainian President Volodymyr Zelenskyy as they meet in the Oval Office of the White House on Dec. 12, 2023, in Washington. President Joe Biden and Ukrainian President Volodymyr Zelenskyy depart a news conference in the Indian Treaty Room in the Eisenhower Executive Office Building on the White House Campus on Dec. 12, 2023, in Washington. President Joe Biden speaks during a funeral service for retired Supreme Court Justice Sandra Day O'Connor at the Washington National Cathedral on Dec. 19, 2023, in Washington. O'Connor, an Arizona native and the first woman to serve on the nation's highest court, died Dec. 1, 2023, at age 93. President Joe Biden arrives to deliver remarks on the economy on June 28, 2023, at the Old Post Office in Chicago. President Joe Biden, right, stands as an Army carry team moves the transfer case containing the remains of U.S. Army Sgt. Kennedy Ladon Sanders, 24, of Waycross, Ga., at Dover Air Force Base, Del., on Feb. 2, 2024. Sanders was killed in a drone attack in Jordan on Jan. 28, 2024. Vice President Kamala Harris embraces President Joe Biden after a speech on health care in Raleigh, N.C., on March. 26, 2024. President Joe Biden greets Zion Schrode, 8 months, of Marin County, Calif., as he is held by his mother Erin Schrode during a Jewish American Heritage Month event, on May 20, 2024, in the Rose Garden of the White House in Washington. Kansas City Chiefs coach Andy Reid, left, and CEO Clark Hunt, right, watch as President Joe Biden, center, puts on a Chiefs helmet during an event with the Super Bowl-champion Kansas City Chiefs on the South Lawn of the White House, on May 31, 2024, to celebrate their championship season and victory in Super Bowl LVIII. President Joe Biden and first lady Jill Biden walk in the Normandy American Cemetery following a ceremony to mark the 80th anniversary of D-Day, on June 6, 2024, in Normandy. U.S. President Joe Biden, right, greets Pope Francis ahead of a working session on Artificial Intelligence (AI), Energy, Africa-Mediterranean, on day two of the 50th G7 summit at Borgo Egnazia, southern Italy, on June 14, 2024. President Joe Biden, right, and Republican presidential candidate former President Donald Trump, left, participate in a presidential debate hosted by CNN on June 27, 2024, in Atlanta. President Joe Biden addresses the nation from the Oval Office of the White House in Washington on July 14, 2024, about the assassination attempt of Republican presidential candidate former President Donald Trump at a campaign rally in Pennsylvania. President Joe Biden pauses as he speaks at the Biden campaign headquarters in Wilmington, Del., on Feb. 3, 2024. President Joe Biden walks between tombstones as he arrives to attend a mass at St. Joseph on the Brandywine Catholic Church in Wilmington, Del., on July 6, 2024. President Joe Biden speaks during the State of the Union address on Capitol Hill on March 7, 2024, in Washington, as Vice President Kamala Harris and House Speaker Mike Johnson listen. President Joe Biden speaks during a campaign event with former President Barack Obama moderated by Jimmy Kimmel at the Peacock Theater on June 15, 2024, in Los Angeles. First lady Jill Biden, President Joe Biden, Vice President Kamala Harris, and second gentleman Douglas Emhoff view the Independence Day firework display over the National Mall from the balcony of the White House, on July 4, 2024, in Washington. President Joe Biden, right, and the Rev. Dr. J. Louis Felton pray at a church service at Mt. Airy Church of God in Christ on July 7, 2024, in Philadelphia. President Joe Biden walks on stage to speak during the NAACP national convention July 16, 2024, in Las Vegas. The poll of 1,251 adults was conducted Dec. 5-9, 2024, using a sample drawn from NORC's probability-based AmeriSpeak Panel, which is designed to be representative of the U.S. population. The margin of sampling error for adults overall is plus or minus 3.7 percentage points. Stay up-to-date on the latest in local and national government and political topics with our newsletter.
Rachel Christian | (TNS) Bankrate.com Just because retirement planning involves some guesswork doesn’t mean it has to be a total mystery. Related Articles Business | The year in money: inflation eased, optimism ticked upward Business | Nearly half of US teens are online ‘constantly,’ Pew report finds Business | How to protect your communications through encryption Business | About 2.6 million Stanley cups recalled after malfunctions caused burns. Is your mug included? Business | Musk says US is demanding he pay penalty over disclosures of his Twitter stock purchases Whether you’ve been saving since your first job or you’re getting a late start, you can leverage expert-recommended strategies to gauge your progress on the road to retirement. And if you’re not quite on track, don’t sweat it — the experts we spoke to offered actionable tips to help you close the gap. You might have a general idea of how much money you need to save for retirement . A few quick calculations can give you an estimate, but to truly appreciate where you stand, you’ll need to dive into the numbers. Here’s how to get started. A good rule of thumb to estimate your retirement savings goal is the Rule of 25 . Simply multiply your desired annual retirement income by 25. The result is roughly how much you’ll need to save before hitting retirement. For example, if you plan to spend $50,000 a year, you’ll need about $1.25 million to make it a reality. The Rule of 25 is based on the idea that withdrawing 4% annually from your retirement savings should last you about 30 years. While it’s not an exact science by any means — health care costs and lifestyle changes can skew the numbers, for example — the Rule of 25 can be a good starting point to figure out how much you need to save. Fidelity Investments, a behemoth in the retirement planning space, offers savings guidelines to help you determine if you’re on track . —By age 30: Save 1x your annual salary —By age 40: Save 3x your annual salary —By age 50: Save 6x your annual salary —By age 60: Save 8x your annual salary —By age 67: Save 10x your annual salary For example, if you earn $60,000 annually, you should aim for $600,000 in savings by age 67. But like the Rule of 25, Fidelity’s guidelines offer a 10,000-foot look at retirement goals, and they’re not customized to your situation. Maybe you earned a low salary in your 20s, but you’re working hard in your 30s to make up for it. Use these estimates as a benchmark — but don’t get discouraged if you’re lagging behind. Now it’s time to zoom in a little. To get a clearer snapshot of your progress, use an online retirement calculator. These tools factor in your age, current savings, income and lifestyle goals to estimate whether you’re on track. You’ll get a more refined estimate without crunching the numbers yourself. Bankrate’s retirement calculator even lets you input different rates of return on your investments and accounts for estimated annual salary increases. Having a general savings goal is nice, but to avoid falling short in retirement, you’ll need more than a ballpark figure. Experts recommend creating a retirement budget to get an up-close-and-personal look at how much you’ll really need once you leave the workforce. First, estimate how much you’ll spend per month in retirement. While some costs will increase, like health care, others will likely decrease, like dining out and commuting. “Estimating expenses can be challenging for some people, so as a starting point, I often use your net take-home pay,” says Jeff DeLarme, a certified financial planner and president of DeLarme Wealth Management. For example, if you receive a direct deposit of $2,500 every two weeks from work, use $5,000 as your estimated monthly spending in retirement. “Assuming this was enough to pay the bills while working, we can use $5,000 a month as a starting budget to plan for,” says DeLarme. Next, map out your sources of income in retirement. Social Security is the largest income stream for most retirees, but don’t neglect other inflows, such as: —Workplace retirement accounts, like 401(k)s —Personal retirement accounts, like a traditional or Roth IRA —Pensions —Annuities —Selling your home or business —Rental income —Inheritance “If there’s a gap between your expected expenses and income, you’ll have a good idea of how much you need to save,” says Mike Hunsberger, a certified financial planner and owner of Next Mission Financial Planning. From there, you can adjust your savings and investment strategy accordingly. For something as important (and complex) as retirement planning, it pays to speak with a professional. Financial advisers can analyze your savings, investments and retirement goals to create a personalized plan. Advisers use special planning software that account for more variables than an online calculator, giving you a much more precise, granular look at your financial life in retirement. Many financial advisers can also help you optimize your tax strategy, which can potentially save you thousands of dollars over time. Make sure the adviser you hire is a fiduciary , meaning they’re legally obligated to prioritize your interests over their own. A fiduciary won’t push investments to earn a commission or recommend products that aren’t aligned with your needs. A certified financial planner is one of the most well-recognized designations for fiduciaries. You can use Bankrate’s adviser matching tool to find a certified financial planner in your area in minutes. Maybe you did the math and realized you’re not quite where you need to be. Don’t panic if you’re behind schedule. Here are five strategies experts recommend to help you catch up on your retirement savings . Cutting expenses now frees up more cash to invest in your retirement accounts. Evaluate your budget and identify areas where you can cut costs, like dining out, streaming subscriptions or shopping. Don’t rule out bigger lifestyle changes either, especially if retirement is rapidly approaching. Housing is the biggest monthly expense for most people. Getting creative here can help amplify the amount you can sock away, says Joseph Boughan, a certified financial planner and managing member at Parkmount Financial Partners. It can also reduce your expenses in retirement, so you may not need to save as much as before. “Downsizing can be a great way to cut expenses,” says Boughan. “This can even free up cash if you don’t end up needing all that money for a new home.” Moving somewhere with lower property taxes or income taxes can also help bring your retirement plan back in line. And if you’re a renter, making tough short-term decisions, like taking on a roommate or moving to a lower cost-of-living area, can free up hundreds of dollars a month for your retirement. “Everyone’s plan is unique, so exploring all the options is important,” Boughan says. Joe Conroy, a certified financial planner and owner of Harford Retirement Planners, recommends taking a “retirement test drive” as you near your target date. “Start to live on what income you think you can afford in retirement and stash all the extra income into savings and investments,” says Conroy. “If you can make it through each month, you’re ready for retirement. If you run short, then adjust your plan accordingly.” Working a little longer can be a game-changer for your retirement nest egg. Not only does it give you more time to save, it also gives your investments room to grow. “Working longer or even just part time for a few years early in retirement is one of the best ways to reduce the amount of money you need to save,” says Hunsberger. Postponing retirement can also boost your Social Security benefits . “You can claim as early as 62, but your benefits will be reduced significantly,” says Hunsberger. Meanwhile, each year you delay claiming Social Security benefits beyond your full retirement age , your monthly check will increase by 8%, though this benefit maxes out at age 70. So waiting can really pay off. It may seem obvious, but if you’re behind on retirement savings, you’ll need to boost your contributions as much as possible. Here are a few ways to make saving for retirement easier: —Increase your contribution rate: Allocate a larger portion of your paycheck to a workplace retirement plan. Even bumping up your contributions by 1% or 2% can make a huge difference down the road. —Take advantage of your employer match: Don’t leave free money on the table. Many employers will chip in between 3 and 5% depending on your plan, so make sure you’re contributing enough to take advantage of the benefit. —Use “unexpected” money to catch up: If you get a raise or bonus at work, funnel part of it directly into your 401(k). And if you get a refund at tax time, siphon some of it off to beef up your IRA. If you’ve been investing in low-risk, low-return investments, you may not be keeping up with inflation, let alone growing your nest egg. Reallocating part of your portfolio to stocks or low-cost growth exchange-traded funds (ETFs) is one way to get your money working harder. Higher-risk investments like stocks carry more volatility but also offer higher potential returns. Work with a financial adviser or use a robo-adviser to strike the right balance between growth and your personal risk tolerance. Contribution limits for 401(k) plans and IRAs are higher for people over 50. For 2025, employees aged 50 and up who participate in most 401(k) plans or the federal government’s Thrift Savings Plan can save up to $31,000 annually, including a $7,500 catch-up contribution . But thanks to SECURE 2.0 , a sweeping retirement law, a new higher catch-up contribution limit of $11,250 applies for employees ages 60 to 63. So, if you’re in this age group, you can squirrel away a whopping $34,750 a year during the final stretch of your career. Of course, you’ll need a big salary (think six figures) in order to take full advantage of such massive contribution limits. But if you can afford it, these catch-up allowances can put your plan back on track, especially if you struggled to save much early in your career. There’s no GPS to gauge your progress on the road to retirement. If you’ve veered off course or aren’t sure where to start, begin by getting a quick estimate of how much you’ll need before mapping out a retirement budget. And if you’re behind, don’t panic — adjusting your spending, boosting your contributions and speaking with a financial adviser can help you catch up. ©2024 Bankrate.com. Distributed by Tribune Content Agency, LLC.100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy SAN DIEGO , Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI ® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. The MajesTEC-5 ( Abstract #493 ) and MajesTEC-4 ( Abstract #494 ) studies establish the potential of TECVAYLI ® for use in newly diagnosed patients, with promising efficacy and a tolerable safety profile. These data were highlighted as oral presentations at the 2024 American Society of Hematology (ASH) Annual Meeting. 1,2 Forty-nine patients with transplant-eligible NDMM were treated with TECVAYLI ® in combination with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj), lenalidomide and dexamethasone (Tec-DRd) or DARZALEX FASPRO ® , bortezomib, lenalidomide and dexamethasone (Tec-DVRd) as induction therapy in the MajesTEC-5 study. 1 All patients who were evaluated for MRD negativity after cycle 3 of induction therapy achieved MRD negativity (10 -5 ) and maintained through cycle 6. 1 "These data from the MajesTEC-5 study build on the growing body of evidence of TECVAYLI combinations that support the potential combinability of TECVAYLI with other effective therapies, demonstrating high rates of MRD-negative responses for evaluable patients with newly diagnosed multiple myeloma," said Rachel Kobos, M.D., Vice President, Oncology Research & Development, Johnson & Johnson Innovative Medicine. "At Johnson & Johnson, our deep expertise and understanding of multiple myeloma has shaped the regimens we're developing, including our bispecific antibodies in new combinations, and we're committed to exploring the full potential of our therapies to improve outcomes for patients." The safety profiles were manageable and consistent with individual safety profiles. 1 No treatment-emergent adverse events (TEAEs) led to study treatment discontinuation or death; cytokine release syndrome (CRS; Grade 1 or 2) occurred in 65 percent of patients. 1 No patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS). 1 Grade 3/4 TEAEs included lymphopenia (43 percent), neutropenia (57 percent) and infections (35 percent). 1 "There remains opportunity to achieve even deeper and more sustained outcomes for a broader patient population in the frontline setting," said Marc S. Raab , M.D., Heidelberg University Hospital, Germany .* "These data reinforce the potential of TECVAYLI when used in earlier lines and show that TECVAYLI can be leveraged to optimize existing standard regimens in combination." Results from the safety run-in of the Phase 3 MajesTEC-4 study highlighted the potential of TECVAYLI ® to be administered as a maintenance therapy following autologous stem cell transplant (ASCT). 2 MajesTEC-4 is the first study to present data on a B-cell maturation antigen (BCMA) bispecific as monotherapy or combination therapy after ASCT. 2 Low rates of non-hematologic Grade 3/4 TEAEs and discontinuation of treatment due to all TEAEs (5.3 percent) were observed. CRS events were all Grade 1/2, mostly occurring during step-up dosing, and ICANS was not observed. Neutropenia and infections were the most common Grade 3/4 TEAEs. 2 Grade 3/4 neutropenia at 6 months showed a decreased trend in cohorts 2 and 3 with less frequent TECVAYLI ® dosing (cohort 1: 94 percent, cohort 2: 63 percent, cohort 3: 47 percent). 2 A similar trend was observed for all-grade infections (cohort 1: 94 percent; cohort 2: 78 percent; cohort 3: 77 percent). 2 All evaluable patients in cohort 1 who underwent MRD assessment after 12 months of therapy were MRD negative, and 100 percent of evaluable patients assessed in cohorts 2 and 3 were also MRD negative at cycle 6. 2 Further analysis of combination therapies will be evaluated in the Phase 3 MajesTEC-7 study, which is currently enrolling. About MajesTEC-5 Study MajesTEC-5 ( NCT05695508 ) is an ongoing, Phase 2 study of teclistamab and talquetamab, evaluating the safety and efficacy of combination regimens in participants with newly diagnosed transplant eligible multiple myeloma. 3 About MajesTEC-4 Study MajesTEC-4 ( NCT05243797 ) is an ongoing, multicenter, randomized, open-label, Phase 3 study of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone in participants with newly diagnosed multiple myeloma as maintenance therapy following autologous stem cell transplantation. 4 About MajesTEC-7 Study MajesTEC-7 ( NCT05552222 ) is a Phase 3 randomized study comparing teclistamab in combination with daratumumab SC and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab SC and lenalidomide (Tal-DR) versus daratumumab SC, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant as initial therapy. 5 About TECVAYLI ® TECVAYLI ® (teclistamab-cqyv) received approval from the U.S. FDA in October 2022 as an off-the-shelf (or ready-to-use) antibody that is administered as a subcutaneous treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. 6 The European Commission (EC) granted TECVAYLI ® conditional marketing authorization (CMA) in August 2022 as monotherapy for the treatment of adult patients with RRMM who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and have demonstrated disease progression since the last therapy. In August 2023 , the EC granted the approval of a Type II variation application for TECVAYLI ® , providing the option for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months. TECVAYLI ® is a first-in-class, bispecific T-cell engager antibody therapy that uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T-cells and to the B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In February 2024 , the U.S. FDA approved the supplemental Biologics License Application (sBLA) for TECVAYLI ® for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory multiple myeloma who have achieved and maintained a CR or better for a minimum of six months. For more information, visit www.TECVAYLI.com . About DARZALEX FASPRO ® and DARZALEX ® DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) received U.S. FDA approval in May 2020 and is approved for nine indications in multiple myeloma, four of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible. It is the only subcutaneous CD38-directed antibody approved to treat patients with MM. DARZALEX FASPRO ® is co-formulated with recombinant human hyaluronidase PH20, Halozyme's ENHANZE ® drug delivery technology. DARZALEX ® is the first CD38-directed antibody approved to treat multiple myeloma. DARZALEX ® -based regimens have been used in the treatment of more than 585,000 patients worldwide and more than 239,000 patients in the U.S. alone. In August 2012 , Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab. For more information, visit https://www.darzalexhcp.com. About Multiple Myeloma Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 7 In multiple myeloma, these plasma cells proliferate and spread rapidly and replace normal cells in the bone marrow with tumors. 8 Multiple myeloma is the third most common blood cancer worldwide and remains an incurable disease. 9 In 2024, it was estimated that more than 35,000 people will be diagnosed with multiple myeloma in the U.S. and more than 12,000 people would die from the disease. 10 People living with multiple myeloma have a 5-year survival rate of 59.8 percent. 11 While some people diagnosed with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels and kidney problems or infections. 12,13 TECVAYLI ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL- ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TECVAYLI ® . Initiate treatment with TECVAYLI ® step-up dosing schedule to reduce risk of CRS. Withhold TECVAYLI ® until CRS resolves or permanently discontinue based on severity. Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and serious and life- threatening reactions, can occur in patients receiving TECVAYLI ® . Monitor patients for signs or symptoms of neurologic toxicity, including ICANS, during treatment. Withhold TECVAYLI ® until neurologic toxicity resolves or permanently discontinue based on severity. TECVAYLI ® is available only through a restricted program called the TECVAYLI ® and TALVEY ® Risk Evaluation and Mitigation Strategy (REMS). INDICATION AND USAGE TECVAYLI ® (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). WARNINGS AND PRECAUTIONS Cytokine Release Syndrome - TECVAYLI ® can cause cytokine release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI ® at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of patients. Most patients experienced CRS following step-up dose 1 (42%), step-up dose 2 (35%), or the initial treatment dose (24%). Less than 3% of patients developed first occurrence of CRS following subsequent doses of TECVAYLI ® . The median time to onset of CRS was 2 (range: 1 to 6) days after the most recent dose with a median duration of 2 (range: 1 to 9) days. Clinical signs and symptoms of CRS included, but were not limited to, fever, hypoxia, chills, hypotension, sinus tachycardia, headache, and elevated liver enzymes (aspartate aminotransferase and alanine aminotransferase elevation). Initiate therapy according to TECVAYLI ® step-up dosing schedule to reduce risk of CRS. Administer pretreatment medications to reduce risk of CRS and monitor patients following administration of TECVAYLI ® accordingly. At the first sign of CRS, immediately evaluate patient for hospitalization. Administer supportive care based on severity and consider further management per current practice guidelines. Withhold or permanently discontinue TECVAYLI ® based on severity. TECVAYLI ® is available only through a restricted program under a REMS. Neurologic Toxicity including ICANS - TECVAYLI ® can cause serious or life-threatening neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). In the clinical trial, neurologic toxicity occurred in 57% of patients who received TECVAYLI ® at the recommended dose, with Grade 3 or 4 neurologic toxicity occurring in 2.4% of patients. The most frequent neurologic toxicities were headache (25%), motor dysfunction (16%), sensory neuropathy (15%), and encephalopathy (13%). With longer follow-up, Grade 4 seizure and fatal Guillain-Barré syndrome (one patient each) occurred in patients who received TECVAYLI ® . In the clinical trial, ICANS was reported in 6% of patients who received TECVAYLI ® at the recommended dose. Recurrent ICANS occurred in 1.8% of patients. Most patients experienced ICANS following step-up dose 1 (1.2%), step-up dose 2 (0.6%), or the initial treatment dose (1.8%). Less than 3% of patients developed first occurrence of ICANS following subsequent doses of TECVAYLI ® . The median time to onset of ICANS was 4 (range: 2 to 8) days after the most recent dose with a median duration of 3 (range: 1 to 20) days. The most frequent clinical manifestations of ICANS reported were confusional state and dysgraphia. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Monitor patients for signs and symptoms of neurologic toxicity during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate patient and provide supportive therapy based on severity. Withhold or permanently discontinue TECVAYLI ® based on severity per recommendations and consider further management per current practice guidelines. Due to the potential for neurologic toxicity, patients are at risk of depressed level of consciousness. Advise patients to refrain from driving or operating heavy or potentially dangerous machinery during and for 48 hours after completion of TECVAYLI ® step-up dosing schedule and in the event of new onset of any neurologic toxicity symptoms until neurologic toxicity resolves. TECVAYLI ® is available only through a restricted program under a REMS. TECVAYLI ® and TALVEY ® REMS - TECVAYLI ® is available only through a restricted program under a REMS called the TECVAYLI ® and TALVEY ® REMS because of the risks of CRS and neurologic toxicity, including ICANS. Hepatotoxicity - TECVAYLI ® can cause hepatotoxicity, including fatalities. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, there was one fatal case of hepatic failure. Elevated aspartate aminotransferase (AST) occurred in 34% of patients, with Grade 3 or 4 elevations in 1.2%. Elevated alanine aminotransferase (ALT) occurred in 28% of patients, with Grade 3 or 4 elevations in 1.8%. Elevated total bilirubin occurred in 6% of patients with Grade 3 or 4 elevations in 0.6%. Liver enzyme elevation can occur with or without concurrent CRS. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Infections - TECVAYLI ® can cause severe, life-threatening, or fatal infections. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, serious infections, including opportunistic infections, occurred in 30% of patients, with Grade 3 or 4 infections in 35%, and fatal infections in 4.2%. Monitor patients for signs and symptoms of infection prior to and during treatment with TECVAYLI ® and treat appropriately. Administer prophylactic antimicrobials according to guidelines. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Monitor immunoglobulin levels during treatment with TECVAYLI ® and treat according to guidelines, including infection precautions and antibiotic or antiviral prophylaxis. Neutropenia - TECVAYLI ® can cause neutropenia and febrile neutropenia. In patients who received TECVAYLI ® at the recommended dose in the clinical trial, decreased neutrophils occurred in 84% of patients, with Grade 3 or 4 decreased neutrophils in 56%. Febrile neutropenia occurred in 3% of patients. Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local institutional guidelines. Monitor patients with neutropenia for signs of infection. Withhold TECVAYLI ® based on severity. Hypersensitivity and Other Administration Reactions - TECVAYLI ® can cause both systemic administration-related and local injection-site reactions. Systemic Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, 1.2% of patients experienced systemic-administration reactions, which included Grade 1 recurrent pyrexia and Grade 1 swollen tongue. Local Reactions - In patients who received TECVAYLI ® at the recommended dose in the clinical trial, injection-site reactions occurred in 35% of patients, with Grade 1 injection-site reactions in 30% and Grade 2 in 4.8%. Withhold TECVAYLI ® or consider permanent discontinuation of TECVAYLI ® based on severity. Embryo-Fetal Toxicity - Based on its mechanism of action, TECVAYLI ® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with TECVAYLI ® and for 5 months after the last dose. ADVERSE REACTIONS The most common adverse reactions (≥20%) were pyrexia, CRS, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, and diarrhea. The most common Grade 3 to 4 laboratory abnormalities (≥20%) were decreased lymphocytes, decreased neutrophils, decreased white blood cells, decreased hemoglobin, and decreased platelets. Please read full Prescribing Information , including Boxed WARNING, for TECVAYLI ® . DARZALEX FASPRO ® INDICATIONS AND IMPORTANT SAFETY INFORMATION INDICATIONS DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS DARZALEX FASPRO ® is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase, or any of the components of the formulation. WARNINGS AND PRECAUTIONS Hypersensitivity and Other Administration Reactions Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO ® . Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO ® . Systemic Reactions In a pooled safety population of 1249 patients with multiple myeloma (N=1056) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO ® as monotherapy or in combination, 7% of patients experienced a systemic administration-related reaction (Grade 2: 3.2%, Grade 3: 0.7%, Grade 4: 0.1%). Systemic administration-related reactions occurred in 7% of patients with the first injection, 0.2% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 2.9 hours (range: 5 minutes to 3.5 days). Of the 165 systemic administration-related reactions that occurred in 93 patients, 144 (87%) occurred on the day of DARZALEX FASPRO ® administration. Delayed systemic administration-related reactions have occurred in 1% of the patients. Severe reactions included hypoxia, dyspnea, hypertension, tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision. Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen, and corticosteroids. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO ® . Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO ® depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions. Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO ® and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO ® . Local Reactions In this pooled safety population, injection-site reactions occurred in 7% of patients, including Grade 2 reactions in 0.8%. The most frequent (>1%) injection-site reaction was injection-site erythema. These local reactions occurred a median of 5 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO ® . Monitor for local reactions and consider symptomatic management. Neutropenia Daratumumab may increase neutropenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO ® until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO ® , higher rates of Grade 3-4 neutropenia were observed. Thrombocytopenia Daratumumab may increase thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO ® until recovery of platelets. Embryo-Fetal Toxicity Based on the mechanism of action, DARZALEX FASPRO ® can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO ® may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO ® and for 3 months after the last dose. The combination of DARZALEX FASPRO ® with lenalidomide, thalidomide, or pomalidomide is contraindicated in pregnant women because lenalidomide, thalidomide, and pomalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, thalidomide, or pomalidomide prescribing information on use during pregnancy. Interference With Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO ® . Type and screen patients prior to starting DARZALEX FASPRO ® . Interference With Determination of Complete Response Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO ® -treated patients with IgG kappa myeloma protein. ADVERSE REACTIONS In multiple myeloma, the most common adverse reaction (≥20%) with DARZALEX FASPRO ® monotherapy is upper respiratory tract infection. The most common adverse reactions with combination therapy (≥20% for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, upper respiratory tract infection, peripheral sensory neuropathy, constipation, pneumonia, and peripheral edema. The most common hematology laboratory abnormalities (≥40%) with DARZALEX FASPRO ® are decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin. Please click here to see the full Prescribing Information for DARZALEX FASPRO ® . About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com . Follow us at @JanssenUS and @JNJInnovMed . Janssen Research & Development, LLC and Janssen Biotech, Inc. are both Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of TECVAYLI ® (teclistamab-cqyv ) and DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc. nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments. * Marc S. Raab , M.D., has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work. 1 Raab, Marc, S., et al, 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 2 Zamagni, Elena, et al., 494 Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the MajesTEC-4/EMN30 Trial. 2024 American Society of Hematology Annual Meeting. December 2024 . 3 GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (HD10/DSMMXX). https://clinicaltrials.gov/study/NCT05695508 . Accessed November 2024 . 4 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4). https://clinicaltrials.gov/study/NCT05243797 . Accessed November 2024 . 5 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7). https://classic.clinicaltrials.gov/ct2/show/NCT05552222 . Accessed November 2024 . 6 U.S. FDA Approves TECVAYLI ® (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. https://www.jnj.com/u-s-fda-approves-tecvayli-teclistamab-cqyv-the-first-bispecific-t-cell-engager-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma . Accessed November 2024 . 7 Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-5672020;95(5):548-567. http://www.ncbi.nlm.nih.gov/pubmed/32212178 8 National Cancer Institute. Plasma Cell Neoplasms. https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq . Accessed November 2024 . 9 City of Hope. Multiple Myeloma: Causes, Symptoms & Treatments. https://www.cancercenter.com/cancer-types/multiple-myeloma . Accessed November 2024 . 10 American Cancer Society. Key Statistics About Multiple Myeloma. https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html#:~:text=Multiple%20myeloma%20is%20a%20relatively,men%20and%2015%2C370%20in%20women . Accessed November 2024 . 11 SEER Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/explorer/ . Accessed November 2024 . 12 American Cancer Society. What is Multiple Myeloma? https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html . Accessed November 2024 . 13 American Cancer Society. Multiple Myeloma Early Detection, Diagnosis, and Staging. https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/detection.html . Accessed November 2024 . Media contacts: Sarah Freeman sfreem21@its.jnj.com Christie Corbett ccorbet6@its.jnj.com Investor contact: Lauren Johnson investor-relations@its.jnj.com U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: https://www.prnewswire.com/news-releases/tecvayli-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma-302325575.html SOURCE Johnson & Johnson
Boise State's legacy includes winning coaches and championship momentsAnalysis: Win or lose at UNC, Belichick's NFL legacy cemented
New Delhi, Dec 24 (IANS): Union Home Minister Amit Shah on Tuesday asked Uttarakhand Chief Minister Pushkar Singh Dhami to make efforts to fill the gaps in technology and other areas for implementation of the three new criminal laws in all police stations of the state. Chairing a review meeting on the implementation of three new criminal laws in Uttarakhand, HM Shah reviewed the implementation and current status of various new provisions related to police, jails, courts, prosecution and forensics in Uttarakhand. Emphasising on the use of technology, the Home Minister said that more than one forensic mobile van should be available in every district of the state. He said that the Uttarakhand Chief Minister should review the progress of implementation of the three new laws every 15 days and the Chief Secretary and DGP once a week with the officials of all the departments concerned. Union Home Secretary, Chief Secretary and the Director General of Police (DGP) of Uttarakhand, Director General of the Bureau of Police Research and Development (BPR&D), Director General of the National Crime Record Bureau (NCRB) and several senior officials of the Ministry of Home Affairs (MHA) and the State government were present in the meeting. During the discussions, HM Shah said that under the leadership of Prime Minister Narendra Modi, the three new criminal laws are becoming the protectors of civil rights and the basis of 'ease of justice'. The Home Minister asked CM Dhami to implement the new criminal laws fully and across all parts of the state as soon as possible. HM Shah said that the new laws are victim and citizen-centric and they need to be implemented promptly with this spirit. The Union Home Minister said that the state government should give priority to the implementation of the new laws in all police stations and jails in areas where more FIRs are registered. HM Shah said that for forensic visits, teams should be divided into three categories -- serious, normal and very normal -- so that resources can be utilised better. Along with this, the Home Minister also emphasised that a protocol should be made to decide the designated place for video conferencing and the cameras installed at all places should be of excellent quality. The Home Minister said that there should be regular and continuous monitoring of how many of the total Zero FIRs registered have been brought to justice and how many FIRs have been transferred to the states. HM Shah suggested the Uttarakhand DGP to ensure that all the Superintendents of Police investigate the cases within the prescribed timelines.South Korean President Faces Critical Impeachment Vote Amid Constitutional Crisis
Automatic Partners with MeridianLink to Revolutionize Lender-Dealership Connectivity
NoneDowntown project gets one step closer
FORESTVILLE, Calif. (AP) — A major storm moving through Northern California on Thursday toppled trees and dropped heavy snow and record rain after damaging homes, killing two people and knocking out power to hundreds of thousands in the Pacific Northwest. Forecasters warned that the risk of flash flooding and rockslides would continue, and scores of flights were canceled at San Francisco's airport. In Washington, more than 320,000 people — most of them in the Seattle area — were still without power as crews worked to clear streets of electrical lines, fallen branches and debris. Utility officials said the outages, which began Tuesday, could last into Saturday. Meanwhile on the East Coast, where rare wildfires have raged, New York and New Jersey welcomed much-needed rain that could ease the fire danger for the rest of the year. The National Weather Service extended a flood watch into Saturday for areas north of San Francisco as the region was inundated by the strongest atmospheric river — a long plume of moisture that forms over an ocean and flows through the sky over land — this season. The system roared ashore Tuesday as a “bomb cyclone,” unleashing fierce winds . Communities in Washington opened warming centers offering free internet and device charging. A number of medical clinics closed because of power outages. “I’ve been here since the mid-’80s. I haven’t seen anything like this,” said Trish Bloor, who serves on the city of Issaquah’s Human Resources Commission, as she surveyed damaged homes. Up to 16 inches (about 41 centimeters) of rain was forecast in southwestern Oregon and California's northern counties through Friday. The Sonoma County Airport, in the wine country north of San Francisco, received 6.92 inches (17.5 centimeters) Wednesday, breaking a record dating to 1998. In nearby Forestville, one person was hurt when a tree fell on a house. Small landslides were reported across the North Bay region, including one on State Route 281 on Wednesday that caused a car crash, according to Marc Chenard, a weather service meteorologist. Rain slowed somewhat, but “persistent heavy rain will enter the picture again by Friday morning,” the weather service's San Francisco office said on the social platform X. “We are not done!” Dangerous flash flooding, rockslides and debris flows were possible, especially where hillsides were loosened by recent wildfires, officials warned. Scott Rowe, a hydrologist with the weather service in Sacramento, said that so far the ground has been able to absorb the rain in California's Butte and Tehama counties, where the Park Fire burned over the summer. “It’s not necessarily how much rain falls; it’s how fast the rain falls,” Rowe said. Northern Mendocino and southern Humboldt counties received between 4 and 8 inches (10 and 20 centimeters) of rain in the last 48 hours, and similar amounts were expected over the next 48 hours, forecasters said. Wind gusts could top 50 mph (80 kph). The storm system, which first hit the Pacific Northwest on Tuesday, reached the status of “ bomb cyclone ,” which occurs when a cyclone intensifies rapidly. A winter storm watch was in place for the northern Sierra Nevada above 3,500 feet (1,066 meters), with 15 inches (38 centimeters) of snow possible over two days. Wind gusts could top 75 mph (121 kph) in mountain areas, forecasters said. Sugar Bowl Resort, north of Lake Tahoe near Donner Summit, picked up a foot (30 centimeters) of snow overnight, marketing manager Maggie Eshbaugh said Thursday. She said the resort will welcome skiers and boarders on Friday, the earliest opening date in 20 years. “And then we’re going to get another whopping of another foot or so on Saturday, so this is fantastic,” she said. Another popular resort, Palisades Tahoe, is also opening Friday, five days ahead of schedule, according to its website. The storm already dumped more than a foot of snow along the Cascades in Oregon by Wednesday night, according to the weather service. Forecasters warned of blizzard and whiteout conditions and nearly impossible travel at pass level. Falling trees struck homes and littered roads across western Washington, killing at least two people. A woman in Lynnwood was killed when a large tree fell on a homeless encampment, and another in Bellevue died when a tree fell on a home. More than a dozen schools closed in the Seattle area Wednesday, and some opted to extend the closures through Thursday. In Enumclaw, east of Seattle, residents were cleaning up after their town clocked the highest winds in the state Tuesday night: 74 mph (119 kph). Resident Sophie Keene said the powerful gusts caused transformers to blow out around town. “Things were exploding, like, everywhere,” Keene told the Seattle Times. “Like the transformers over by the park. One blew big, it looked like fireworks just going off.” Ben Gibbard, lead singer of the indie rock bands Death Cab for Cutie and Postal Service, drove from his Seattle neighborhood Thursday morning to the woods of Tiger Mountain for his regular weekday run, but there were too many trees blocking the trail. “We didn’t get hit that hard in the city,” he said. “I just didn’t assume it would be this kind of situation out here. Obviously you feel the most for people who had their homes partially destroyed by this.” In California, there were reports of more than 20,000 power outages on Thursday. Only 50 vehicles per hour were allowed through part of northbound Interstate 5 from 10 miles (16 kilometers) north of Redding to 21 miles (34 kilometers) south of Yreka due to snow, according to California's Department of Transportation. Transportation officials also shut down a two-mile (3.2 kilometer) stretch of the famed Avenue of the Giants, a scenic drive named for its towering coast redwoods, due to flooding. About 150 flights were delayed and another two dozen were canceled early Thursday at San Francisco International Airport after hundreds of delays and dozens of cancelations the previous day, according to tracking service FlightAware. Parched areas of the Northeast got a much-needed shot of precipitation Thursday, providing a bit of respite in a region plagued by wildfires and dwindling water supplies. More than 2 inches (5 centimeters) of rain was expected by Saturday morning in areas north of New York City, with snow mixed in at higher elevations. “Any rainfall is going to be significant at this point,” said Brian Ciemnecki, a weather service meteorologist in New York City, where the first drought warning in 22 years was issued this week. “Is it going to break the drought? No, we’re going to need more rain than that.” Har reported from San Francisco, and Weber from Los Angeles. Associated Press writers Hallie Golden and Gene Johnson in Seattle; Martha Bellisle in Issaquah, Washington; Sarah Brumfield in Washington, D.C.; and Michael Hill in Albany, New York, contributed.
Oreo O's have been replaced by another cookie-themed cerealTECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myelomaBill Belichick didn't wait around for a call that he might not get from an NFL team. With no guarantees that another opportunity might come his way — only the Atlanta Falcons interviewed Belichick last offseason — and unsure whether he could find the right fit in the NFL, the 72-year-old future Hall of Fame coach decided to go back to school. Belichick took his eight Super Bowl rings to North Carolina on a mission to build a college program the way he constructed two dynasties during 24 seasons with the New England Patriots. It starts with doing things his way. The Patriot Way is legendary. Perhaps it'll translate into the Tar Heel way. That's to be determined. But Belichick is back doing what he loves: coaching. And, he's going to run the show with his guys around him. An NFL team giving Belichick full control the way he had in New England seemed unlikely. Success at North Carolina could change that thinking. For now, Belichick's quest to break Don Shula's all-time record for most wins in the NFL is on hold. He's 15 victories short but the buyout clause in his college contract — a $10 million fee if done before June 2025 and $1 million after that date — leaves the window open for a return to the league. If Belichick stays in college or retires without returning to the NFL, his legacy is already cemented. Winning at North Carolina will only enhance his reputation. Losing won't impact his NFL resume. "He's one of the all-time great coaches. What he's done for the NFL and the game, we all know where he'll end up — in the Hall of Fame with a gold jacket," Dallas Cowboys executive Stephen Jones said Wednesday shortly before Belichick agreed on a five-year deal with North Carolina that pays him $10 million in base and supplemental salary annually with up to $3.5 million in bonuses per year. Belichick has his detractors. There's no denying he couldn't win without Tom Brady. He was 29-39 and had no playoff wins without No. 12 in his final four seasons with the Patriots. Critics have labeled him a cheater because of the Spygate and Deflategate scandals. He overlooked Aaron Hernandez's issues. He was tough on players, even alienating Brady in the end and letting him walk him away in free agency in 2020 only to see him lead the Tampa Bay Buccaneers to a Super Bowl in his first season there. But Belichick instilled in players the importance of doing their job and presided over an unprecedented two-decade run of dominance that withstood changing times, free agency, salary-cap restrictions and much more. Brady has always maintained how important Belichick was for his career, giving him credit for helping him become one of the best players in sports. Now, Belichick is onto Chapel Hill in a surprise twist after he spent most of the NFL season reinventing himself as an entertaining and engaging analyst. Belichick is a football genius and his knowledge came across on television. But he also displayed a fun personality, trading quips with the Mannings and cracking jokes with Pat McAffee. "College kind of came to me this year," Belichick said at his introductory news conference. "I didn't necessarily go and seek it out. I had many coaches, probably a couple dozen coaches, talk to me and say, 'Can we come down and talk to you about these things?' Let's call it the salary cap of pro football relative to college football. The headsets, the green dot, the two-minute warning, the tablets on the sideline. Those were all rules changes this year for college football that were either or the same or similar to what we had in the NFL. These coaches said, 'Hey coach can we talk to you about how you did this? How you did that? How did you use this?'. "As those conversations started and then the personnel conversations started relative to salary cap and how you spend whatever the allotment of money you have. I'd say that started to make me a lot more aware of it because the first thing I would have to do is learn about it. .... As you learn different things about different programs you start to put it all together. There is some common threads and there's some variables." How will he do as a college coach? Nobody knows yet. Three of Belichick's former players were skeptical before he took the job. "There's a lot of things he can do, and obviously he's tremendous, and even showing his personality. But getting out there on the recruiting trail and dealing with all these college kids, that would be ..." Brady said before trailing off during a conversation on Fox's NFL pregame show last Sunday. Fellow former Patriots Rob Gronkowski and Julian Edelman also wondered the same. "Can you imagine NIL, and all that nonsense?" Gronkowski said. Edelman added: "Can you imagine Bill on a couch recruiting an 18-year-old?" But Belichick doesn't have to recruit kids on visits. These are new times in college sports. The NIL has dramatically changed the landscape. Plus, Belichick's name is enough. Just like Deion Sanders at Colorado. "I think it could be great for this game, honestly, if he can find a way to make college football more like this in terms of what's being asked of the coaches, the recruiting staff, the personnel, the NIL, and all those different things," Tampa Bay Buccaneers offensive coordinator Liam Cohen said. "If he can make it a little bit less demanding on some of the coaches and create a great atmosphere and have success, I think it's great for our game. It's pretty cool to see, actually." Time for Belichick to do his job. Get local news delivered to your inbox!
The Tampa Bay Buccaneers head to California this week to take on the Los Angeles Chargers. They’ll do so without three key members of their defense. Via Fox Sports Greg Auman , “Bowles says Winfield, Edwards and Britt are ruled out. Irving and Izien are both questionable.” Bowles on running back Bucky Irving and defensive back Christian Izien via the team’s website , “They’re questionable right now,” said Bowles. “We’ll see as it gets closer to the game. We may have to work them out beforehand to see how they feel.” Rookie Bucky Irving has been a bright spot for the Buccaneers, rushing for 735 yards and a team-leading six touchdowns, while averaging an impressive 5.4 yards per carry. He’s also been a reliable receiver out of the backfield, hauling in 36 passes. However, Irving’s recent performances have been impacted by injuries, including a back issue that forced him to exit last Sunday’s game against the Raiders early, as well as a hip ailment he suffered the previous weekend in Charlotte. Christian Izien has been a versatile and vital component of Todd Bowles’ defense, filling various roles in the secondary amidst a slew of injuries. He’s seamlessly transitioned between slot, free safety, and outside cornerback, showcasing his adaptability. Izien’s flexibility was on full display against the Raiders, where he played multiple positions. With Antoine Winfield Jr. and Mike Edwards already sidelined for Sunday’s game, the Buccaneers’ defensive alignment against the Chargers will heavily depend on the availability of another key player, Bucky Irving . As mentioned, linebacker K.J. Britt has also been ruled out with an ankle injury. Look for the Buccaneers to use more single linebacker sets as they did against Las Vegas last week. This article first appeared on Bucs Report and was syndicated with permission.College Football Playoff's first 12-team bracket is set with Oregon No. 1 and SMU in, Alabama out